Press Releases

Sep 15, 2020	Summary Toggle Enzon Pharmaceuticals Announces Key Dates for Rights Offering CRANFORD, N.J. , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced today the record date and expected subscription period for its previously-announced rights offering to raise proceeds of approximately $43 million . The proceeds from the
Sep 2, 2020	Summary Toggle Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting CRANFORD, N.J. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 2020 annual meeting of stockholders (the “Annual Meeting”) originally scheduled to be held on Thursday, September 17, 2020 , has been postponed and will now
Aug 21, 2020	Summary Toggle Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders CRANFORD, N.J. , Aug. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC: ENZN) today announced that its Board of Directors (the “Board”) has approved a rights offering to existing shareholders whereby the Company intends to distribute one transferable
Aug 14, 2020	Summary Toggle Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value CRANFORD, N.J. , Aug. 14, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its Board of Directors (the “Board”) adopted a tax benefits preservation plan (the “Section 382 Rights Plan”) designed to protect the availability of Enzon’s net
May 1, 2014	Summary Toggle Enzon Adopts Stockholder Rights Plan in an Effort to Protect Net Operating Loss Carryforwards PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc.	Enzon Adopts Stockholder Rights Plan in an Effort to Protect Net Operating Loss Carryforwards 11.8 KB
Apr 23, 2013	Summary Toggle Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces $1.60 Special Dividend and Periodic Royalty Dividends PISCATAWAY, NJ -- (Marketwired) -- 04/23/13 -- Enzon Pharmaceuticals, Inc.	Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces $1.60 Special Dividend and Periodic Royalty Dividends 13 KB
Mar 18, 2013	Summary Toggle Enzon Reports Fourth Quarter and Full Year 2012 Results PISCATAWAY, NJ -- (Marketwire) -- 03/18/13 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the fourth quarter and full year 2012.	Enzon Reports Fourth Quarter and Full Year 2012 Results 25.5 KB
Dec 17, 2012	Summary Toggle Enzon to Review Asset Sales, Sale of the Company PISCATAWAY, NJ -- (Marketwire) -- 12/17/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that its Board of Directors has retained Lazard to act as financial advisor in a review of the possible sale or disposition of one or more corporate assets, or a sale of the Company.	Enzon to Review Asset Sales, Sale of the Company 11.3 KB
Nov 29, 2012	Summary Toggle Enzon Announces Special Dividend PISCATAWAY, NJ -- (Marketwire) -- 11/29/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that its Board of Directors has authorized a special dividend of $2.00 per common share, payable on December 21, 2012 to shareholders of record as of December 10, 2012 .	Enzon Announces Special Dividend 10.5 KB
Nov 8, 2012	Summary Toggle Enzon Announces Two Oral Presentations at the Symposium of Drug Delivery Systems in Nanjing, China PISCATAWAY, NJ -- (Marketwire) -- 11/08/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced two oral presentations at the 2nd Annual Symposium of Drug Delivery Systems-2012, which is being held November 8-10 in Nanjing , China .	Enzon Announces Two Oral Presentations at the Symposium of Drug Delivery Systems in Nanjing, China 14.2 KB